United States Burden of Melanoma and Non-Melanoma Skin Cancer from 1990 to 2019.

BACKGROUND: Skin cancer is the most common cancer worldwide.

OBJECTIVE: To evaluate burden of skin cancer in the US from 1990 to 2019.

METHODS: Age-standardized incidence, prevalence, disability adjusted life years (DALY) and mortality rates from skin cancer in the US were evaluated from the Global Burden of Disease (GBD) 2019.

RESULTS: Incidence, prevalence, DALY and mortality rates per 100,000 persons from melanoma in 2019 were 17.0, 138, 64.8 and 2.2, respectively; for squamous cell carcinoma (SCC) were 262, 314, 26.6 and 0.8, respectively; and for basal cell carcinoma were 525, 51.2, 0.2 and zero, respectively. Incidence as well as prevalence rates of melanoma and non-melanoma skin cancer (NMSC) have increased since 1990. Mortality rates from melanoma and NMSC have remained fairly stable. Males have had a higher incidence, prevalence, DALY and mortality rate from melanoma as well as from NMSC every year since 1990. Incidence and prevalence of melanoma was relatively higher in the northern half of the US than in the southern half.

LIMITATIONS: GBD is derived from estimation and mathematical modeling.

CONCLUSIONS: Healthcare professionals can utilize differences and trends noted in this study to guide allocation of resources in order to reduce incidence and morbidity from skin cancer.